JeRiCHO: JAK-inhibition in Recurrent Classical Hodgkin Lymphoma

Sponsor
University of Cologne (Other)
Overall Status
Completed
CT.gov ID
NCT02164500
Collaborator
(none)
12
1
1
43.5
0.3

Study Details

Study Description

Brief Summary

The Purpose of this trial is:
  • to determine the overall response rate (ORR, complete response [CR] + partial response [PR]) in patients with relapsed or refractory HL

  • to determine the safety profile of ruxolitinib in patients with relapsed or refractory HL

Condition or Disease Intervention/Treatment Phase
Phase 2

Study Design

Study Type:
Interventional
Actual Enrollment :
12 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase II, Open-label, Prospective, Non-randomized, Multicenter Clinical Trial With the JAK-inhibitor Ruxolitinib in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Study Start Date :
Oct 1, 2015
Actual Primary Completion Date :
May 17, 2019
Actual Study Completion Date :
May 17, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Ruxolitinib

Drug: Ruxolitinib

Outcome Measures

Primary Outcome Measures

  1. overall response rate [8 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • relapsed or refractory HL

  • ECOG <= 2,

  • no major organ dysfunction

  • written informed consent

Exclusion Criteria:
  • history of another primary malignancy ≤ 2 years

  • female patients who are pregnant or breast feeding

  • patients with a known history of HIV seropositivity

  • chronic active hepatitis

Contacts and Locations

Locations

Site City State Country Postal Code
1 1st Dept. of Medicine, Cologne University Hospital Cologne Germany 50924

Sponsors and Collaborators

  • University of Cologne

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Dr. Bastian von Tresckow, Dr., University of Cologne
ClinicalTrials.gov Identifier:
NCT02164500
Other Study ID Numbers:
  • JeRiCHO
First Posted:
Jun 16, 2014
Last Update Posted:
Apr 6, 2020
Last Verified:
Apr 1, 2020
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 6, 2020